MBX vs. BCT, IPA, TH, APS, SCYB, COM, NVH, IGX, MDNA, and PDP
Should you be buying Microbix Biosystems stock or one of its competitors? The main competitors of Microbix Biosystems include BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Aptose Biosciences (APS), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry.
Microbix Biosystems vs. Its Competitors
Microbix Biosystems (TSE:MBX) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Microbix Biosystems had 5 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 5 mentions for Microbix Biosystems and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 beat Microbix Biosystems' score of -1.00 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.
Microbix Biosystems received 30 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. Likewise, 70.00% of users gave Microbix Biosystems an outperform vote while only 68.97% of users gave BriaCell Therapeutics an outperform vote.
Microbix Biosystems has a net margin of 13.86% compared to BriaCell Therapeutics' net margin of 0.00%. Microbix Biosystems' return on equity of 12.65% beat BriaCell Therapeutics' return on equity.
0.4% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Microbix Biosystems has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.
Summary
Microbix Biosystems beats BriaCell Therapeutics on 11 of the 12 factors compared between the two stocks.
Get Microbix Biosystems News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Microbix Biosystems Competitors List
Related Companies and Tools
This page (TSE:MBX) was last updated on 6/12/2025 by MarketBeat.com Staff
